← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Avm Biotechnology, Llc
Seattle, WA
$5,458,747
Total funding
6
Grants
Funding over time
peak $2.1M · FY2019–25$2.5M$1.9M$1.3M$625K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,458,747 · 6
By mechanism
R44$4,623,737 · 3
R43$835,010 · 3
Investigators at Avm Biotechnology, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Expedited Expansion Cohort Clinical Trial for Relapsed/Refractory 'no-option' Non-Hodgkin's Lymphoma/Leukemia Patients$999,999
R44 · FY2023 · CA
Expedited Expansion Cohort Clinical Trial for Relapsed/Refractory 'no-option' Non-Hodgkin's Lymphoma/Leukemia Patients$999,999
R44 · FY2022 · CA
Immunomodulatory AVM0703 to bridge Relapsed/Refractory Diffuse Large B-Cell Lymphoma patients to CAR-T cell immunotherapy$992,425
R44 · FY2025 · CA
Targeted Lymphoablation as an alternative to HSCT to cure T1D$963,581
R44 · FY2023 · DK
Targeted Lymphoablation as an alternative to HSCT to cure T1D$667,733
R44 · FY2022 · DK
AVM0703 combined with Non-Hodgkin's Lymphoma standard of care to enhance complete response rates without additional toxicities$399,193
R43 · FY2022 · CA
A novel non-toxic preconditioning regimen for cancer cell therapy$224,770
R43 · FY2020 · CA
Targeted lympho-ablation as an alternative to HSCT to cure T1D$211,047
R43 · FY2019 · DK